BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 17523848)

  • 1. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
    Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
    Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
    J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
    Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
    Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
    Günther M; Waxman DJ; Wagner E; Ogris M
    Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
    Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
    Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro.
    Chen JK; Hu LJ; Wang D; Lamborn KR; Deen DF
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1538-47. PubMed ID: 17394949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bystander effects induced by continuous low-dose-rate 125I seeds potentiate the killing action of irradiation on human lung cancer cells in vitro.
    Chen HH; Jia RF; Yu L; Zhao MJ; Shao CL; Cheng WY
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1560-6. PubMed ID: 19028278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
    Hay MP; Wilson WR; Denny WA
    Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
    De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
    Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
    Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
    Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.